Oxford's Corona vaccine can be found in India for only Rs 225

England, Ta. 8 August 2020, Saturday

The number of corona cases in India is now increasing very fast and India has topped the list in terms of the number of daily infections. In these circumstances people are now sitting there hoping for the outcome of the trial of the corona vaccine. In this case, people have high hopes for the vaccine from Oxford University, whose human trial is in its final stages.

According to a report, poor and middle class families in India can get this vaccine for only Rs 225. Modern America, Russia and Oxford University are among the companies and countries leading the world in developing corona vaccine. The Serum Institute of India, one of the largest vaccine manufacturers in the world, is also a partner in the corona vaccine being developed at Oxford University.

Following the successful trial of the corona vaccine being developed at Oxford University, the Serum Institute of India will start mass production in India. Adar Poonawala, CEO of the company, said a few days ago that the vaccine would be sold in India under the name Covishield and could cost up to Rs 1,000.

However, according to a report, the serum company will sell the corona vaccine in India for only Rs 225. The Oxford AstraZeneca Covid-19 vaccine is likely to be sold in low- and middle-income countries for just ડો 3, or about Rs 225, after security clearance.

It is natural to question how the company will make the vaccine available at such a cheap price. But the Gates Foundation is the answer because it is providing a risk fund of about 150 150 million to vaccine companies. This money will help the serum company reduce production costs. "The widespread spread of the virus has left the entire world in a state of uncertainty," said Adar Poonawala, CEO, Serum Institute of India. It is important to ensure that affordable treatment and prevention measures reach even the poorest and poorest countries in the world to prevent vaccinations and epidemics around the world. Through this association, we want to make continuous efforts to save the lives of millions of people from this terrible disease.

The Oxford University vaccine was approved last week to begin second and third phase trials in India. Novaxin testing in India is still awaiting approval.